Wixela inhub and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Wixela inhub (fluticasone propionate; salmeterol xinafoate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Pantoprazole, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Nosebleed when taking Wixela inhub. It is created by eHealthMe based on reports of 2,900 people who have side effects when taking Wixela inhub from the FDA, and is updated regularly.

What is Wixela inhub?

Wixela inhub has active ingredients of fluticasone propionate; salmeterol xinafoate. eHealthMe is studying from 2,925 Wixela inhub users. Check the latest studies of Wixela inhub.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,080 drugs and 3,093 conditions by eHealthMe. Check the latest studies of Nosebleed.

On Jul, 12, 2026

2,900 people reported to have side effects when taking Wixela inhub.
Among them, 13 people (0.45%) have Nosebleed.

Among these 13 people:

How long have people been on Wixela inhub when they have Nosebleed? *

What is the gender of people who have Nosebleed when taking Wixela inhub? *

female: 61.54 %
male: 38.46 %

What is the age of people who have Nosebleed when taking Wixela inhub? *

What are other drugs people take besides Wixela inhub? *

What are other side effects people have besides Nosebleed? *

Nasal Dryness (dry nose): 3 people, 23.08%
Anaemia (lack of blood): 3 people, 23.08%
Coughing Up Blood: 2 people, 15.38%
Skin Infection: 1 person, 7.69%
Secretion Discharge: 1 person, 7.69%
Rhinalgia (pain in the nose): 1 person, 7.69%
Respiratory Tract Inflammation: 1 person, 7.69%
Pulmonary Mass: 1 person, 7.69%
Pneumonia: 1 person, 7.69%
Lung Neoplasm (tumour of lung): 1 person, 7.69%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 5 people, 38.46%
Nasal Polyps (masses that develop in the lining of the nose): 2 people, 15.38%
Asthma: 2 people, 15.38%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 7.69%
Hypersensitivity: 1 person, 7.69%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 1 person, 7.69%
Dyspnea (difficult or laboured breathing): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Wixela inhub and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Wixela inhub:

Wixela inhub (2,925 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

How severe was Nosebleed and when was it recovered:

Nosebleed in Wixela inhub

Expand to all the drugs that have ingredients of fluticasone propionate; salmeterol xinafoate:

Nosebleed and drugs with ingredients of fluticasone propionate; salmeterol xinafoate (1,140 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Wixela inhub:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,080 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,093 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fluticasone propionate; salmeterol xinafoate (the active ingredients of Wixela inhub) and Wixela inhub (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.